ClinicalTrials.gg
Active, not recruitingNCT03761498Updated Apr 1, 2025

Is There a Microbiome Associated With Poor Growth in Preterm Infants?

An observational study in Growth Disorders, Growth Failure and Prematurity, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by University of Texas Southwestern Medical Center · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
118
Sex
All
01

Study summary

This study evaluates the relationship between growth and stool microbiota in premature infants.

Read the detailed description

Preterm infants often require increased caloric intake to maintain appropriate growth while in the neonatal intensive care unit (NICU). While some infants will have a clear source of need for greater calories, it is often not obvious why others require increased available calories to maintain appropriate growth. Emerging evidence suggests that patterns of gut microbiota may play a role in infant and childhood growth. We hypothesize that differences in the microbial pattern in preterm infants is related to poor growth and need for increased caloric intake. This may ultimately represent a therapeutic target to improve the growth of preterm infants in the NICU. This study aims to describe the differences in microbiome which may vary with growth pattern.

02

Conditions studied

  • Growth Disorders
  • Growth Failure
  • Prematurity
03

In context

Growth Disorders

227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.

This study's enrollment of 118 is below the median of 231 across 78 observational studies indexed under Growth Disorders.

Browse Growth Disorders studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,010 studies on the registry; 199 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Preterm infants born at less than 28 weeks gestation will be eligible from birth until discharge. Infants with major congenital anomalies which alter growth patterns will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All infants less than 28 weeks gestation who are admitted to the Parkland Hospital NICU.

Exclusion criteria

Exclusion Criteria:

Infants >27 weeks gestation. Infants with major congenital anomalies which may alter growth patterns.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
118 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Normal Growth

    Require less than or equal to 110 kcal/kg/day to maintain growth curve

  • Slow Growth

    Require more than 110 kcal/kg/day to maintain growth curve

    Other: Caloric Requirement

Interventions

  • OtherCaloric Requirement

    Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.

06

What researchers measure

Primary outcomes

  1. quantitative rT-PCR of stool microbiome

    alpha diversity of bacterial groups in normal growth vs. poor growth

    Time frame: 8-10 weeks depending on length of stay in NICU

07

Study locations

1 site
  • Parkland Hopsital and Health System
    Dallas, Texas 75235, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Dec 2025, 77 months after the start.

Of 42 observational studies under Growth Disorders, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Dec 3, 2018
StartActual
Jul 15, 2019
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03761498
Responsible party
Katherine Anne Stumpf (Assistant Professor of Pediatrics, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Dec 3, 2018
Start date
Jul 15, 2019
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Apr 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion